Testicular cancer treatment: which is easier on patients?
NCT ID NCT07498959
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at men with good-prognosis metastatic testicular cancer to see if surgery (RPLND) leads to a better quality of life than chemotherapy. About 160 men over 18 will be followed to measure side effects and daily well-being. The goal is to find which treatment causes fewer long-term problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- primary retroperitoneal lymph node dissection (RPLND) and chemotherapy (Bleomycin, Etoposide, Platinum)
- What this could lead to
- If successful, this study could show that surgery causes fewer side effects than chemotherapy for certain testicular cancers, helping guide treatment choices.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also relatively small and early-stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DE-ESCALATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sahlgrenska University Hospital
RECRUITINGGothenburg, Göteborg, 413 45, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Tape to tame Post-Surgery face swelling?
- Can a virtual meadow or a Mind's eye stream calm hospital anxiety?
- Smartwatch could spot nerve damage before it starts
- Can healing at home beat hospital care for bedsores?
- Can virtual reality make knee pain therapy more engaging?
- Can sound waves outperform needles for Jumper's knee?